Previous Study: TRIO019
Next Study: TRIO021

Studies & Results


A randomized open-label Phase II study of letrozole plus afatinib (BIBW2992) versus letrozole alone in first-line treatment of advanced ER+, HER2- postmenopausal breast cancer with low ER expression

View FDA Study View EU Study

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at